Key result
Inotuzumab ozogamicin causes no clinically meaningful QTc prolongation, with median increases under 10 ms.
Why the study?
The effect of inotuzumab ozogamicin on the QT interval in patients with B-cell malignancies needed to be characterized.
Answers are grounded in this paper and cite their sources.
Reveals negligible QT prolongation with inotuzumab ozogamicin in hematologic malignancies, indicating low cardiac safety risk.
Aim The aim of this study was to characterize the effect of inotuzumab ozogamicin on QT interval in patients with B‐cell malignancies. Methods Data were pooled from three clinical studies including 250 patients (n = 2743) who received inotuzumab ozogamicin monotherapy. Patients with relapsed/refractory acute lymphoblastic leukaemia (NCT01564784 and NCT01363297) received 1.8 mg m−2 per cycle in divided doses (mean Cmax 371 ng ml−1; considered therapeutic) and patients with relapsed/refractory non‐Hodgkin lymphoma (NCT00868608) received 1.8 mg m−2 per cycle as a single dose (mean Cmax 569 ng ml−1; considered supratherapeutic). Triplicate 12‐lead electrocardiograms were performed at baseline and predefined time points postdose with paired pharmacokinetic collections. The exposure–response relationship between corrected QT interval (QTc: QT interval corrected using population‐specific formula [QTcS] or QT interval corrected using Fridericia's formula [QTcF]) and inotuzumab ozogamicin concentration was characterized using a linear mixed‐effects model, and simulations were performed using the final validated model. Full model development involved testing for covariates that may account for part of the identified variability. Results QTc intervals had a small but positive correlation with inotuzumab ozogamicin concentration. Based on 1000 simulations, median (upper 95% CI) QTcS and QTcF changes from baseline were <10 ms at both therapeutic (2.70 ms [5.40 ms] and 2.53 ms [4.92 ms], respectively) and supratherapeutic (4.14 ms [8.28 ms] and 3.87 ms [7.54 ms], respectively) concentrations. Conclusions Inotuzumab ozogamicin (1.8 mg m−2 per cycle) is not predicted to pose a clinically significant safety risk for QT prolongation in patients with acute lymphoblastic leukaemia or non‐Hodgkin lymphoma.
No takes yet. Share an insight, caveat, or question.
Hibma et al. (2018) studied B-cell malignancies (relapsed/refractory acute lymphoblastic leukaemia and relapsed/refractory non-Hodgkin lymphoma) (n=250). Inotuzumab ozogamicin was evaluated on Corrected QT interval (QTcS and QTcF) change from baseline (95% CI upper 95% CI 5.40 ms). Inotuzumab ozogamicin yielded median QTcS and QTcF increases <10 ms at therapeutic and supratherapeutic concentrations.
Synapse has enriched 10 related papers. Consider them for comparative context: